About geovax labs - GOVX
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola-Zaire, Ebola-Sudan, Lassa, Marburg, Zika virus and malaria. The company was founded in June 1988 and is headquartered in Smyrna, GA.
GOVX At a Glance
GeoVax Labs, Inc.
1955 Lake Park Drive
Smyrna, Georgia 30080
| Phone | 1-678-384-7220 | Revenue | 2.49M | |
| Industry | Biotechnology | Net Income | -21,464,771.00 | |
| Sector | Health Technology | Employees | 19 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GOVX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.646 |
| Price to Book Ratio | 1.936 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.086 |
| Enterprise Value to Sales | 0.745 |
| Total Debt to Enterprise Value | 0.455 |
GOVX Efficiency
| Revenue/Employee | 131,007.632 |
| Income Per Employee | -1,129,724.789 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.087 |
GOVX Liquidity
| Current Ratio | 2.744 |
| Quick Ratio | 2.744 |
| Cash Ratio | 1.593 |
GOVX Profitability
| Gross Margin | 97.238 |
| Operating Margin | -869.337 |
| Pretax Margin | -862.335 |
| Net Margin | -862.335 |
| Return on Assets | -74.768 |
| Return on Equity | -483.786 |
| Return on Total Capital | -459.798 |
| Return on Invested Capital | -454.103 |
GOVX Capital Structure
| Total Debt to Total Equity | 22.043 |
| Total Debt to Total Capital | 18.062 |
| Total Debt to Total Assets | 1.712 |
| Long-Term Debt to Equity | 15.164 |
| Long-Term Debt to Total Capital | 12.425 |